Helix BioPharma Company Executives
| HBP Stock | CAD 0.77 0.07 10.00% |
Helix BioPharma employs about 7 people. The company is managed by 8 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 0.88 employees per reported executive. Analysis of Helix BioPharma's management performance can provide insight into the firm performance.
| Artur Gabor Chairman CEO Chairman |
Helix |
Helix BioPharma Management Team Effectiveness
The company has return on total asset (ROA) of (4.5865) % which means that it has lost $4.5865 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (22.2062) %, meaning that it generated substantial loss on money invested by shareholders. Helix BioPharma's management efficiency ratios could be used to measure how well Helix BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Helix BioPharma's Return On Capital Employed is very stable compared to the past year. As of the 23rd of November 2024, Return On Equity is likely to grow to 108.08, though Return On Tangible Assets are likely to grow to (5.91). At this time, Helix BioPharma's Other Current Assets are very stable compared to the past year. As of the 23rd of November 2024, Debt To Assets is likely to grow to 0.86, while Total Assets are likely to drop about 1.4 M.As of the 23rd of November 2024, Common Stock Shares Outstanding is likely to grow to about 96.5 M, while Net Loss is likely to drop (7.6 M).
Helix BioPharma Workforce Comparison
Helix BioPharma Corp is rated # 3 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 139. Helix BioPharma holds roughly 7.0 in number of employees claiming about 5% of equities under Health Care industry.
Helix BioPharma Corp Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Helix BioPharma Corp Price Series Summation is a cross summation of Helix BioPharma price series and its benchmark/peer.
Helix BioPharma Notable Stakeholders
A Helix BioPharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Helix BioPharma often face trade-offs trying to please all of them. Helix BioPharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Helix BioPharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jacek Antas | Chairman CEO | Profile | |
| Artur Gabor | CEO Chairman | Profile | |
| FCA FCA | CFO Secretary | Profile | |
| Namrata Malhotra | Corporate Secretary | Profile | |
| Dr MA | Head RD | Profile | |
| Srikanth Sola | Chief Officer | Profile | |
| Christof Boehler | Chief Officer | Profile | |
| MBA MBA | Chief Officer | Profile |
About Helix BioPharma Management Performance
The success or failure of an entity such as Helix BioPharma Corp often depends on how effective the management is. Helix BioPharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Helix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Helix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (6.22) | (5.91) | |
| Return On Capital Employed | 104.12 | 109.33 | |
| Return On Assets | (6.22) | (5.91) | |
| Return On Equity | 102.93 | 108.08 |
Helix BioPharma Workforce Analysis
Traditionally, organizations such as Helix BioPharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Helix BioPharma within its industry.Helix BioPharma Manpower Efficiency
Return on Helix BioPharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 1.2M |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.